drugset / Trial / NCT00538902

Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00538902

Phase 2/3 Completed 302 enrolled Abbott
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to assess the safety and efficacy of adalimumab administered as a subcutaneous injection in adult Chinese subjects with rheumatoid arthritis and treated with methotrexate

Timeline

Start
2007-08
Primary completion
2008-07
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Adalimumab Monoclonal antibody 80 mg Subcutaneous

Indications